nodes	percent_of_prediction	percent_of_DWPC	metapath
Penicillamine—Hepatic failure—Dactinomycin—sarcoma	0.00727	0.00727	CcSEcCtD
Penicillamine—Hepatic failure—Vincristine—sarcoma	0.0065	0.0065	CcSEcCtD
Penicillamine—Neuropathy—Etoposide—sarcoma	0.00612	0.00612	CcSEcCtD
Penicillamine—Optic neuritis—Epirubicin—sarcoma	0.00594	0.00594	CcSEcCtD
Penicillamine—Eruption—Epirubicin—sarcoma	0.00594	0.00594	CcSEcCtD
Penicillamine—Mouth ulceration—Etoposide—sarcoma	0.00589	0.00589	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Dactinomycin—sarcoma	0.00588	0.00588	CcSEcCtD
Penicillamine—Thrombocytosis—Epirubicin—sarcoma	0.00587	0.00587	CcSEcCtD
Penicillamine—Optic neuritis—Doxorubicin—sarcoma	0.00549	0.00549	CcSEcCtD
Penicillamine—Eruption—Doxorubicin—sarcoma	0.00549	0.00549	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Etoposide—sarcoma	0.00544	0.00544	CcSEcCtD
Penicillamine—Thrombocytosis—Doxorubicin—sarcoma	0.00543	0.00543	CcSEcCtD
Penicillamine—Bone marrow depression—Epirubicin—sarcoma	0.00541	0.00541	CcSEcCtD
Penicillamine—Pancytopenia—Thiotepa—sarcoma	0.0054	0.0054	CcSEcCtD
Penicillamine—Pancytopenia—Dactinomycin—sarcoma	0.00536	0.00536	CcSEcCtD
Penicillamine—Abdominal pain upper—Mitoxantrone—sarcoma	0.00519	0.00519	CcSEcCtD
Penicillamine—Muscular weakness—Vincristine—sarcoma	0.00515	0.00515	CcSEcCtD
Penicillamine—Bone marrow depression—Doxorubicin—sarcoma	0.00501	0.00501	CcSEcCtD
Penicillamine—Renal failure—Thiotepa—sarcoma	0.00499	0.00499	CcSEcCtD
Penicillamine—Stomatitis—Thiotepa—sarcoma	0.00495	0.00495	CcSEcCtD
Penicillamine—Stomatitis—Dactinomycin—sarcoma	0.00491	0.00491	CcSEcCtD
Penicillamine—Haematuria—Thiotepa—sarcoma	0.00484	0.00484	CcSEcCtD
Penicillamine—Hepatobiliary disease—Thiotepa—sarcoma	0.0048	0.0048	CcSEcCtD
Penicillamine—Pancytopenia—Vincristine—sarcoma	0.00479	0.00479	CcSEcCtD
Penicillamine—Rash erythematous—Epirubicin—sarcoma	0.00477	0.00477	CcSEcCtD
Penicillamine—Agranulocytosis—Thiotepa—sarcoma	0.00474	0.00474	CcSEcCtD
Penicillamine—Agranulocytosis—Dactinomycin—sarcoma	0.0047	0.0047	CcSEcCtD
Penicillamine—Pancytopenia—Mitoxantrone—sarcoma	0.00467	0.00467	CcSEcCtD
Penicillamine—Haemoglobin—Thiotepa—sarcoma	0.00458	0.00458	CcSEcCtD
Penicillamine—Haemorrhage—Thiotepa—sarcoma	0.00456	0.00456	CcSEcCtD
Penicillamine—Ageusia—Epirubicin—sarcoma	0.00451	0.00451	CcSEcCtD
Penicillamine—Urinary tract disorder—Thiotepa—sarcoma	0.0045	0.0045	CcSEcCtD
Penicillamine—Urethral disorder—Thiotepa—sarcoma	0.00447	0.00447	CcSEcCtD
Penicillamine—Rash erythematous—Doxorubicin—sarcoma	0.00441	0.00441	CcSEcCtD
Penicillamine—Neuropathy peripheral—Vincristine—sarcoma	0.00441	0.00441	CcSEcCtD
Penicillamine—Stomatitis—Vincristine—sarcoma	0.00439	0.00439	CcSEcCtD
Penicillamine—Renal failure—Mitoxantrone—sarcoma	0.00431	0.00431	CcSEcCtD
Penicillamine—Stomatitis—Mitoxantrone—sarcoma	0.00427	0.00427	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Etoposide—sarcoma	0.00426	0.00426	CcSEcCtD
Penicillamine—Tinnitus—Thiotepa—sarcoma	0.00425	0.00425	CcSEcCtD
Penicillamine—Extravasation—Epirubicin—sarcoma	0.00419	0.00419	CcSEcCtD
Penicillamine—Haematuria—Mitoxantrone—sarcoma	0.00418	0.00418	CcSEcCtD
Penicillamine—Ageusia—Doxorubicin—sarcoma	0.00417	0.00417	CcSEcCtD
Penicillamine—Angiopathy—Thiotepa—sarcoma	0.00413	0.00413	CcSEcCtD
Penicillamine—Agranulocytosis—Mitoxantrone—sarcoma	0.00409	0.00409	CcSEcCtD
Penicillamine—Alopecia—Thiotepa—sarcoma	0.00403	0.00403	CcSEcCtD
Penicillamine—Alopecia—Dactinomycin—sarcoma	0.00399	0.00399	CcSEcCtD
Penicillamine—Mental disorder—Thiotepa—sarcoma	0.00399	0.00399	CcSEcCtD
Penicillamine—Urinary tract disorder—Vincristine—sarcoma	0.00399	0.00399	CcSEcCtD
Penicillamine—Glossitis—Epirubicin—sarcoma	0.00396	0.00396	CcSEcCtD
Penicillamine—Urethral disorder—Vincristine—sarcoma	0.00396	0.00396	CcSEcCtD
Penicillamine—Haemoglobin—Mitoxantrone—sarcoma	0.00395	0.00395	CcSEcCtD
Penicillamine—Haemorrhage—Mitoxantrone—sarcoma	0.00393	0.00393	CcSEcCtD
Penicillamine—Pancytopenia—Etoposide—sarcoma	0.00388	0.00388	CcSEcCtD
Penicillamine—Extravasation—Doxorubicin—sarcoma	0.00387	0.00387	CcSEcCtD
Penicillamine—Glossitis—Doxorubicin—sarcoma	0.00367	0.00367	CcSEcCtD
Penicillamine—Anaemia—Thiotepa—sarcoma	0.00366	0.00366	CcSEcCtD
Penicillamine—Angiopathy—Vincristine—sarcoma	0.00366	0.00366	CcSEcCtD
Penicillamine—Agitation—Thiotepa—sarcoma	0.00364	0.00364	CcSEcCtD
Penicillamine—Anaemia—Dactinomycin—sarcoma	0.00364	0.00364	CcSEcCtD
Penicillamine—Renal failure—Etoposide—sarcoma	0.00358	0.00358	CcSEcCtD
Penicillamine—Neuropathy peripheral—Etoposide—sarcoma	0.00357	0.00357	CcSEcCtD
Penicillamine—Alopecia—Vincristine—sarcoma	0.00357	0.00357	CcSEcCtD
Penicillamine—Stomatitis—Etoposide—sarcoma	0.00355	0.00355	CcSEcCtD
Penicillamine—Leukopenia—Thiotepa—sarcoma	0.00355	0.00355	CcSEcCtD
Penicillamine—Mental disorder—Vincristine—sarcoma	0.00354	0.00354	CcSEcCtD
Penicillamine—Leukopenia—Dactinomycin—sarcoma	0.00352	0.00352	CcSEcCtD
Penicillamine—Alopecia—Mitoxantrone—sarcoma	0.00348	0.00348	CcSEcCtD
Penicillamine—Hepatobiliary disease—Etoposide—sarcoma	0.00345	0.00345	CcSEcCtD
Penicillamine—Aplastic anaemia—Epirubicin—sarcoma	0.00343	0.00343	CcSEcCtD
Penicillamine—Neuropathy—Epirubicin—sarcoma	0.00343	0.00343	CcSEcCtD
Penicillamine—Agranulocytosis—Etoposide—sarcoma	0.0034	0.0034	CcSEcCtD
Penicillamine—Arthralgia—Thiotepa—sarcoma	0.00338	0.00338	CcSEcCtD
Penicillamine—Anxiety—Thiotepa—sarcoma	0.00336	0.00336	CcSEcCtD
Penicillamine—Dysgeusia—Mitoxantrone—sarcoma	0.00335	0.00335	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00335	0.00335	CcSEcCtD
Penicillamine—Mouth ulceration—Epirubicin—sarcoma	0.0033	0.0033	CcSEcCtD
Penicillamine—Anaemia—Vincristine—sarcoma	0.00325	0.00325	CcSEcCtD
Penicillamine—Urinary tract disorder—Etoposide—sarcoma	0.00323	0.00323	CcSEcCtD
Penicillamine—Agitation—Vincristine—sarcoma	0.00323	0.00323	CcSEcCtD
Penicillamine—Urethral disorder—Etoposide—sarcoma	0.00321	0.00321	CcSEcCtD
Penicillamine—Aplastic anaemia—Doxorubicin—sarcoma	0.00317	0.00317	CcSEcCtD
Penicillamine—Neuropathy—Doxorubicin—sarcoma	0.00317	0.00317	CcSEcCtD
Penicillamine—Thrombocytopenia—Thiotepa—sarcoma	0.00317	0.00317	CcSEcCtD
Penicillamine—Anaemia—Mitoxantrone—sarcoma	0.00316	0.00316	CcSEcCtD
Penicillamine—Leukopenia—Vincristine—sarcoma	0.00315	0.00315	CcSEcCtD
Penicillamine—Thrombocytopenia—Dactinomycin—sarcoma	0.00314	0.00314	CcSEcCtD
Penicillamine—Skin disorder—Thiotepa—sarcoma	0.00314	0.00314	CcSEcCtD
Penicillamine—Lymphadenopathy—Epirubicin—sarcoma	0.00311	0.00311	CcSEcCtD
Penicillamine—Anorexia—Thiotepa—sarcoma	0.00308	0.00308	CcSEcCtD
Penicillamine—Leukopenia—Mitoxantrone—sarcoma	0.00307	0.00307	CcSEcCtD
Penicillamine—Thrombophlebitis—Epirubicin—sarcoma	0.00306	0.00306	CcSEcCtD
Penicillamine—Anorexia—Dactinomycin—sarcoma	0.00306	0.00306	CcSEcCtD
Penicillamine—Mouth ulceration—Doxorubicin—sarcoma	0.00306	0.00306	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Epirubicin—sarcoma	0.00305	0.00305	CcSEcCtD
Penicillamine—Hepatic function abnormal—Epirubicin—sarcoma	0.00303	0.00303	CcSEcCtD
Penicillamine—Angiopathy—Etoposide—sarcoma	0.00297	0.00297	CcSEcCtD
Penicillamine—Hepatic failure—Epirubicin—sarcoma	0.00295	0.00295	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00295	0.00295	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00293	0.00293	CcSEcCtD
Penicillamine—Arthralgia—Mitoxantrone—sarcoma	0.00292	0.00292	CcSEcCtD
Penicillamine—Anxiety—Mitoxantrone—sarcoma	0.00291	0.00291	CcSEcCtD
Penicillamine—Alopecia—Etoposide—sarcoma	0.00289	0.00289	CcSEcCtD
Penicillamine—Lymphadenopathy—Doxorubicin—sarcoma	0.00288	0.00288	CcSEcCtD
Penicillamine—Thrombophlebitis—Doxorubicin—sarcoma	0.00283	0.00283	CcSEcCtD
Penicillamine—Blood alkaline phosphatase increased—Doxorubicin—sarcoma	0.00282	0.00282	CcSEcCtD
Penicillamine—Decreased appetite—Thiotepa—sarcoma	0.00281	0.00281	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Epirubicin—sarcoma	0.00281	0.00281	CcSEcCtD
Penicillamine—Thrombocytopenia—Vincristine—sarcoma	0.00281	0.00281	CcSEcCtD
Penicillamine—Hepatic function abnormal—Doxorubicin—sarcoma	0.00281	0.00281	CcSEcCtD
Penicillamine—Decreased appetite—Dactinomycin—sarcoma	0.00279	0.00279	CcSEcCtD
Penicillamine—Dysgeusia—Etoposide—sarcoma	0.00279	0.00279	CcSEcCtD
Penicillamine—Thrombocytopenia—Mitoxantrone—sarcoma	0.00274	0.00274	CcSEcCtD
Penicillamine—Anorexia—Vincristine—sarcoma	0.00274	0.00274	CcSEcCtD
Penicillamine—Hepatic failure—Doxorubicin—sarcoma	0.00273	0.00273	CcSEcCtD
Penicillamine—Hypoglycaemia—Epirubicin—sarcoma	0.00272	0.00272	CcSEcCtD
Penicillamine—Skin disorder—Mitoxantrone—sarcoma	0.00271	0.00271	CcSEcCtD
Penicillamine—Anorexia—Mitoxantrone—sarcoma	0.00266	0.00266	CcSEcCtD
Penicillamine—Anaemia—Etoposide—sarcoma	0.00263	0.00263	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Vincristine—sarcoma	0.00261	0.00261	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Doxorubicin—sarcoma	0.0026	0.0026	CcSEcCtD
Penicillamine—Urticaria—Thiotepa—sarcoma	0.00257	0.00257	CcSEcCtD
Penicillamine—Body temperature increased—Thiotepa—sarcoma	0.00256	0.00256	CcSEcCtD
Penicillamine—Leukopenia—Etoposide—sarcoma	0.00255	0.00255	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00255	0.00255	CcSEcCtD
Penicillamine—Body temperature increased—Dactinomycin—sarcoma	0.00254	0.00254	CcSEcCtD
Penicillamine—Hypoglycaemia—Doxorubicin—sarcoma	0.00251	0.00251	CcSEcCtD
Penicillamine—Decreased appetite—Vincristine—sarcoma	0.00249	0.00249	CcSEcCtD
Penicillamine—Decreased appetite—Mitoxantrone—sarcoma	0.00243	0.00243	CcSEcCtD
Penicillamine—Abdominal pain upper—Epirubicin—sarcoma	0.00242	0.00242	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00241	0.00241	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.00239	0.00239	CcSEcCtD
Penicillamine—Hypersensitivity—Thiotepa—sarcoma	0.00238	0.00238	CcSEcCtD
Penicillamine—Hypersensitivity—Dactinomycin—sarcoma	0.00237	0.00237	CcSEcCtD
Penicillamine—Muscular weakness—Epirubicin—sarcoma	0.00234	0.00234	CcSEcCtD
Penicillamine—Asthma—Epirubicin—sarcoma	0.00229	0.00229	CcSEcCtD
Penicillamine—Thrombocytopenia—Etoposide—sarcoma	0.00228	0.00228	CcSEcCtD
Penicillamine—Eosinophilia—Epirubicin—sarcoma	0.00227	0.00227	CcSEcCtD
Penicillamine—Body temperature increased—Vincristine—sarcoma	0.00227	0.00227	CcSEcCtD
Penicillamine—Skin disorder—Etoposide—sarcoma	0.00226	0.00226	CcSEcCtD
Penicillamine—Pancreatitis—Epirubicin—sarcoma	0.00225	0.00225	CcSEcCtD
Penicillamine—Abdominal pain upper—Doxorubicin—sarcoma	0.00224	0.00224	CcSEcCtD
Penicillamine—Urticaria—Mitoxantrone—sarcoma	0.00222	0.00222	CcSEcCtD
Penicillamine—Anorexia—Etoposide—sarcoma	0.00222	0.00222	CcSEcCtD
Penicillamine—Diarrhoea—Thiotepa—sarcoma	0.00221	0.00221	CcSEcCtD
Penicillamine—Body temperature increased—Mitoxantrone—sarcoma	0.00221	0.00221	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.00221	0.00221	CcSEcCtD
Penicillamine—Diarrhoea—Dactinomycin—sarcoma	0.0022	0.0022	CcSEcCtD
Penicillamine—Pancytopenia—Epirubicin—sarcoma	0.00218	0.00218	CcSEcCtD
Penicillamine—Muscular weakness—Doxorubicin—sarcoma	0.00216	0.00216	CcSEcCtD
Penicillamine—Asthma—Doxorubicin—sarcoma	0.00212	0.00212	CcSEcCtD
Penicillamine—Hypersensitivity—Vincristine—sarcoma	0.00211	0.00211	CcSEcCtD
Penicillamine—Eosinophilia—Doxorubicin—sarcoma	0.0021	0.0021	CcSEcCtD
Penicillamine—Pancreatitis—Doxorubicin—sarcoma	0.00208	0.00208	CcSEcCtD
Penicillamine—Hypersensitivity—Mitoxantrone—sarcoma	0.00206	0.00206	CcSEcCtD
Penicillamine—Vomiting—Thiotepa—sarcoma	0.00206	0.00206	CcSEcCtD
Penicillamine—Vomiting—Dactinomycin—sarcoma	0.00204	0.00204	CcSEcCtD
Penicillamine—Rash—Thiotepa—sarcoma	0.00204	0.00204	CcSEcCtD
Penicillamine—Dermatitis—Thiotepa—sarcoma	0.00204	0.00204	CcSEcCtD
Penicillamine—Rash—Dactinomycin—sarcoma	0.00203	0.00203	CcSEcCtD
Penicillamine—Decreased appetite—Etoposide—sarcoma	0.00202	0.00202	CcSEcCtD
Penicillamine—Pancytopenia—Doxorubicin—sarcoma	0.00201	0.00201	CcSEcCtD
Penicillamine—Renal failure—Epirubicin—sarcoma	0.00201	0.00201	CcSEcCtD
Penicillamine—Neuropathy peripheral—Epirubicin—sarcoma	0.002	0.002	CcSEcCtD
Penicillamine—Stomatitis—Epirubicin—sarcoma	0.00199	0.00199	CcSEcCtD
Penicillamine—Diarrhoea—Vincristine—sarcoma	0.00196	0.00196	CcSEcCtD
Penicillamine—Haematuria—Epirubicin—sarcoma	0.00195	0.00195	CcSEcCtD
Penicillamine—Hepatobiliary disease—Epirubicin—sarcoma	0.00193	0.00193	CcSEcCtD
Penicillamine—Nausea—Thiotepa—sarcoma	0.00192	0.00192	CcSEcCtD
Penicillamine—Diarrhoea—Mitoxantrone—sarcoma	0.00191	0.00191	CcSEcCtD
Penicillamine—Nausea—Dactinomycin—sarcoma	0.00191	0.00191	CcSEcCtD
Penicillamine—Agranulocytosis—Epirubicin—sarcoma	0.00191	0.00191	CcSEcCtD
Penicillamine—Renal failure—Doxorubicin—sarcoma	0.00186	0.00186	CcSEcCtD
Penicillamine—Neuropathy peripheral—Doxorubicin—sarcoma	0.00185	0.00185	CcSEcCtD
Penicillamine—Urticaria—Etoposide—sarcoma	0.00185	0.00185	CcSEcCtD
Penicillamine—Haemoglobin—Epirubicin—sarcoma	0.00184	0.00184	CcSEcCtD
Penicillamine—Stomatitis—Doxorubicin—sarcoma	0.00184	0.00184	CcSEcCtD
Penicillamine—Body temperature increased—Etoposide—sarcoma	0.00184	0.00184	CcSEcCtD
Penicillamine—Haemorrhage—Epirubicin—sarcoma	0.00183	0.00183	CcSEcCtD
Penicillamine—Vomiting—Vincristine—sarcoma	0.00182	0.00182	CcSEcCtD
Penicillamine—Urinary tract disorder—Epirubicin—sarcoma	0.00181	0.00181	CcSEcCtD
Penicillamine—Rash—Vincristine—sarcoma	0.00181	0.00181	CcSEcCtD
Penicillamine—Dermatitis—Vincristine—sarcoma	0.00181	0.00181	CcSEcCtD
Penicillamine—Haematuria—Doxorubicin—sarcoma	0.0018	0.0018	CcSEcCtD
Penicillamine—Urethral disorder—Epirubicin—sarcoma	0.0018	0.0018	CcSEcCtD
Penicillamine—Hepatobiliary disease—Doxorubicin—sarcoma	0.00179	0.00179	CcSEcCtD
Penicillamine—Vomiting—Mitoxantrone—sarcoma	0.00178	0.00178	CcSEcCtD
Penicillamine—Agranulocytosis—Doxorubicin—sarcoma	0.00176	0.00176	CcSEcCtD
Penicillamine—Rash—Mitoxantrone—sarcoma	0.00176	0.00176	CcSEcCtD
Penicillamine—Dermatitis—Mitoxantrone—sarcoma	0.00176	0.00176	CcSEcCtD
Penicillamine—Hypersensitivity—Etoposide—sarcoma	0.00171	0.00171	CcSEcCtD
Penicillamine—Tinnitus—Epirubicin—sarcoma	0.00171	0.00171	CcSEcCtD
Penicillamine—Haemoglobin—Doxorubicin—sarcoma	0.00171	0.00171	CcSEcCtD
Penicillamine—Nausea—Vincristine—sarcoma	0.0017	0.0017	CcSEcCtD
Penicillamine—Haemorrhage—Doxorubicin—sarcoma	0.0017	0.0017	CcSEcCtD
Penicillamine—Urinary tract disorder—Doxorubicin—sarcoma	0.00168	0.00168	CcSEcCtD
Penicillamine—Angiopathy—Epirubicin—sarcoma	0.00166	0.00166	CcSEcCtD
Penicillamine—Urethral disorder—Doxorubicin—sarcoma	0.00166	0.00166	CcSEcCtD
Penicillamine—Nausea—Mitoxantrone—sarcoma	0.00166	0.00166	CcSEcCtD
Penicillamine—Alopecia—Epirubicin—sarcoma	0.00162	0.00162	CcSEcCtD
Penicillamine—Mental disorder—Epirubicin—sarcoma	0.00161	0.00161	CcSEcCtD
Penicillamine—Diarrhoea—Etoposide—sarcoma	0.00159	0.00159	CcSEcCtD
Penicillamine—Tinnitus—Doxorubicin—sarcoma	0.00158	0.00158	CcSEcCtD
Penicillamine—Dysgeusia—Epirubicin—sarcoma	0.00156	0.00156	CcSEcCtD
Penicillamine—Angiopathy—Doxorubicin—sarcoma	0.00154	0.00154	CcSEcCtD
Penicillamine—Alopecia—Doxorubicin—sarcoma	0.0015	0.0015	CcSEcCtD
Penicillamine—Mental disorder—Doxorubicin—sarcoma	0.00149	0.00149	CcSEcCtD
Penicillamine—Vomiting—Etoposide—sarcoma	0.00148	0.00148	CcSEcCtD
Penicillamine—Anaemia—Epirubicin—sarcoma	0.00148	0.00148	CcSEcCtD
Penicillamine—Agitation—Epirubicin—sarcoma	0.00147	0.00147	CcSEcCtD
Penicillamine—Rash—Etoposide—sarcoma	0.00147	0.00147	CcSEcCtD
Penicillamine—Dermatitis—Etoposide—sarcoma	0.00146	0.00146	CcSEcCtD
Penicillamine—Dysgeusia—Doxorubicin—sarcoma	0.00145	0.00145	CcSEcCtD
Penicillamine—Leukopenia—Epirubicin—sarcoma	0.00143	0.00143	CcSEcCtD
Penicillamine—Nausea—Etoposide—sarcoma	0.00138	0.00138	CcSEcCtD
Penicillamine—Anaemia—Doxorubicin—sarcoma	0.00137	0.00137	CcSEcCtD
Penicillamine—Arthralgia—Epirubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Penicillamine—Agitation—Doxorubicin—sarcoma	0.00136	0.00136	CcSEcCtD
Penicillamine—Anxiety—Epirubicin—sarcoma	0.00135	0.00135	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00135	0.00135	CcSEcCtD
Penicillamine—Leukopenia—Doxorubicin—sarcoma	0.00132	0.00132	CcSEcCtD
Penicillamine—Thrombocytopenia—Epirubicin—sarcoma	0.00128	0.00128	CcSEcCtD
Penicillamine—Skin disorder—Epirubicin—sarcoma	0.00127	0.00127	CcSEcCtD
Penicillamine—Arthralgia—Doxorubicin—sarcoma	0.00126	0.00126	CcSEcCtD
Penicillamine—Anxiety—Doxorubicin—sarcoma	0.00125	0.00125	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00125	0.00125	CcSEcCtD
Penicillamine—Anorexia—Epirubicin—sarcoma	0.00124	0.00124	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00119	0.00119	CcSEcCtD
Penicillamine—Thrombocytopenia—Doxorubicin—sarcoma	0.00118	0.00118	CcSEcCtD
Penicillamine—Skin disorder—Doxorubicin—sarcoma	0.00117	0.00117	CcSEcCtD
Penicillamine—Anorexia—Doxorubicin—sarcoma	0.00115	0.00115	CcSEcCtD
Penicillamine—Decreased appetite—Epirubicin—sarcoma	0.00113	0.00113	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.0011	0.0011	CcSEcCtD
Penicillamine—Decreased appetite—Doxorubicin—sarcoma	0.00105	0.00105	CcSEcCtD
Penicillamine—Urticaria—Epirubicin—sarcoma	0.00104	0.00104	CcSEcCtD
Penicillamine—Body temperature increased—Epirubicin—sarcoma	0.00103	0.00103	CcSEcCtD
Penicillamine—Hypersensitivity—Epirubicin—sarcoma	0.00096	0.00096	CcSEcCtD
Penicillamine—Urticaria—Doxorubicin—sarcoma	0.000958	0.000958	CcSEcCtD
Penicillamine—Body temperature increased—Doxorubicin—sarcoma	0.000953	0.000953	CcSEcCtD
Penicillamine—Diarrhoea—Epirubicin—sarcoma	0.000892	0.000892	CcSEcCtD
Penicillamine—Hypersensitivity—Doxorubicin—sarcoma	0.000888	0.000888	CcSEcCtD
Penicillamine—Vomiting—Epirubicin—sarcoma	0.000829	0.000829	CcSEcCtD
Penicillamine—Diarrhoea—Doxorubicin—sarcoma	0.000825	0.000825	CcSEcCtD
Penicillamine—Rash—Epirubicin—sarcoma	0.000822	0.000822	CcSEcCtD
Penicillamine—Dermatitis—Epirubicin—sarcoma	0.000821	0.000821	CcSEcCtD
Penicillamine—Nausea—Epirubicin—sarcoma	0.000774	0.000774	CcSEcCtD
Penicillamine—Vomiting—Doxorubicin—sarcoma	0.000767	0.000767	CcSEcCtD
Penicillamine—Rash—Doxorubicin—sarcoma	0.00076	0.00076	CcSEcCtD
Penicillamine—Dermatitis—Doxorubicin—sarcoma	0.00076	0.00076	CcSEcCtD
Penicillamine—Nausea—Doxorubicin—sarcoma	0.000716	0.000716	CcSEcCtD
